Watson Pharmaceuticals Invests in $15M New Jersey Expansion
05/27/2010
"Over the past year, we have outgrown our current administrative headquarters site, as our U.S. and global business has rapidly grown," said Paul Biscaro, Watson president and CEO. "This new facility will ensure that we have a single location for the leadership and shared services functions that are driving our global growth."
New Jersey's Business Employment Incentive Program (BEIP) has extended Watson a grant of approximately $7.3 million over the next 10 years from the state's Economic Development Authority. It has also been approved for a $290,000 Business Retention and Relocation Assistance Grant (BRRAG) to retain 200 jobs in New Jersey.
Watson was the country's third largest producer of generic drugs in 2009 based on prescriptions dispensed. It specializes in drugs for urology and women's health.
Most Read
-
-
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
-
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
-
A Changing Food Manufacturing Industry
2017 Food Processing
-
What Should High-Growth Companies Look for in a Community?
Q4 2019
-
Front Line: Trend Toward Microfactories Continues
Q4 2019
-
2019 Gold & Silver Shovel Awards: Recipients Garnered Large Job-Creating and Investment Projects in Diverse Industries
Q2 2019